Macquarie Group
DNTH icon

Macquarie Group’s Dianthus Therapeutics DNTH Stock Holding History

Macquarie Group’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,824
Closed -$55 – 1963
2024
Q1 		$55 Buy
+1,824
New +$39.6K ﹤0.01% 1649

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Macquarie Group's DNTH Position: Q2 2024 in Review

Macquarie Group sold out of Dianthus Therapeutics (DNTH) in Q2 2024, closing a stake of 1,824 shares — an estimated $55 sold.

Macquarie Group first reported a position in DNTH in Q1 2024 and held it in 1 quarter. The position peaked at $55 in Q1 2024. 74 funds tracked by Wall St. Rank hold DNTH as of Q2 2024.

  • Macquarie Group reported no remaining Dianthus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Macquarie Group sold 1,824 Dianthus Therapeutics shares in Q2 2024, an estimated $55.
  • Macquarie Group first reported a position in Dianthus Therapeutics in Q1 2024 and held it in 1 quarter.
  • Macquarie Group's Dianthus Therapeutics position peaked at $55 in Q1 2024.
  • 74 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.